JMP Securities Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated his 'Market Outperform' rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a price target of $70.
October 18, 2023 | 1:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals has received a 'Market Outperform' rating from JMP Securities, with a maintained price target of $70.
The 'Market Outperform' rating from JMP Securities indicates a positive outlook for Mirum Pharmaceuticals. This could potentially attract investors and drive the stock price up in the short term. The maintained price target of $70 also suggests that the analyst believes the stock is undervalued at current levels.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100